Drug intelligence / Profile preview

streptomycin

Development stage
Approved
Lead developer
Merck
Modality
Small Molecules
Administration
Intramuscular, Intravenous
01

Overview

Streptomycin is an aminoglycoside antibiotic that functions as a protein synthesis inhibitor. It exerts its antibacterial effect by irreversibly binding to the 16S ribosomal RNA (rRNA) of the bacterial 30S ribosomal subunit. This binding interferes with the attachment of formyl-methionyl-tRNA, leading to misreading of the messenger RNA (mRNA) and premature termination of protein synthesis. The disruption of essential protein production ultimately results in bacterial cell death. Discovered in 1943 by Albert Schatz from the bacterium Streptomyces griseus, under the supervision of Selman Waksman, streptomycin was the first antibiotic found to be effective against tuberculosis. It is a broad-spectrum antibiotic active against various Gram-positive and Gram-negative bacteria, and is used to treat a range of bacterial infections including tuberculosis, plague, tularemia, brucellosis, and certain forms of endocarditis.

Brand names
Ambistryn-SStreptomacStrilinAgreptAgrimycinStreptomycin A
Other names
streptomycin
02

Targets

Bacterial 23S ribosomal RNA (23S rRNA) cryptic site30S A-site (Bacterial ribosomal 30S A-site)S12 (Small ribosomal subunit protein uS12)DHQS (3-dehydroquinate synthase)

Beyond the preview

Go deeper on streptomycin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on streptomycin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call